(RTTNews) - STAAR Surgical Company (STAA) revealed earnings for its third quarter that increased from last year and beat the Street estimates. The company's earnings came in at $10.0 million ...

Anthony Petrone has given his Buy rating due to a combination of factors including Staar Surgical’s robust performance in Japan and EMEA, which counterbalanced challenges in the US and China markets.

STAAR Surgical Company beats earnings expectations. Reported EPS is $0.41, expectations were $0.19. Operator: Greetings and welcome to the STAAR Surgical Third Quarter 2024 Earnings Webcast. As a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Evaluate Staar Surgical's (STAA) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance. Staar Surgical Co ...

Staar Surgical STAA will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Staar Surgical to ...

KSEAB 2nd PUC Class 12th Biology Model Paper 2025: The Karnataka School Examination and Assessment Board (KSEAB) has released the subject-wise model papers for 2nd PUC students. These model papers ...

A first-of-its-kind blood test that uses biomarkers to distinguish bipolar disorder from depression could slash the time it ...

Charles Darwin is famous for proposing the theory of evolution by natural selection, but how much more do you know about the British naturalist?

Qiagen NV added to its growing roster of panels cleared by the U.S. FDA in 2024 with the agency’s nod for its Qiastat-Dx Meningitis/Encephalitis assay. The clearance validates Qiagen’s strategy of ...

Nov. 11, 2024 — Researchers have named two newly discovered freshwater snail species from Brazil after characters from The Lord of the ...

A2 Bio shares clinical study progress and the increased diversity of participants in the BASECAMP-1 prescreening study during the SITC annual meeting.